Triple Negative Breast Cancer Clinical Trial

Trial Summary

A Multi-Center, Dose Finding, Open Label, Phase 1 Study of RX-5902 in Subjects With Advanced or Metastatic Solid Tumors

More Information on this Clinical Trial

Frequently Asked Questions

A Clinical Trial is a type of research study that examines how well a potential therapy works in humans.

The purpose of this Phase 2 portion of the study is to use the dose and schedule of RX-5902 identified in Phase 1 to treat subjects with triple negative breast cancer.

This clinical trial has certain criteria that a person has to meet to determine if they can participate. After you have discussed the trial with your doctor, specific tests will be done to see if you qualify for this study.

Rexahn Pharmaceuticals, Inc. is sponsoring this clinical trial.

There will be a total of 20 patients enrolled in this clinical trial.

Have your physician complete the contact form.